The health insurance directory announces the countdown to a group of medical representatives or affected

Pharmaceutical Network December 21st, 2020 health care negotiations ended, the catalog published in that, the product or not, the relevant pharmaceutical representatives or by a greater impact.
1, the health insurance catalog announced into the countdown day, the three-day 2020 national health insurance drug catalog access negotiations officially concluded.
it is understood that the negotiations mainly involve cancer, mental illness, eye disease, pediatrics and other drug varieties, the follow-up successful drug negotiations will enter the National Health Insurance Class B drug catalog, according to previous experience, if you want to ensure that 2021, health insurance negotiations drugs officially landed, health insurance drug catalog may be published in recent days.
According to public reports in the relevant media, the drugs that surfaced in the first day of negotiations included products from the first day of negotiations or drugs related to Chinese medicine, rare diseases, as well as some diabetes medications, such as No.
The products negotiated on the second day may contain some anti-cancer drugs, cardiovascular drugs, eye drugs, etc., involving AstraZeneca, Xi'an Jansen, Reding, Green leaf pharmaceutical, etc., as well as domestic innovative drugs - the treatment of Alzheimer's disease new drug Ghanlutna capsule (GV-971). on the third day of the
, the most attention was paid to the anti-cancer drugs led by PD-1, as well as some Chinese medicines, in addition to China Biopharmaceuticals' Arodini, Haussen's Amethini, and Baiji Shenzhou's Zebtini.
Sources pointed out that in the third day of negotiations, Hengrui's Karelli pearl single resistance fell to about 3000 yuan per unit, do not calculate charitable gifts, a decrease or more than 80%, in exchange for four approved adaptation certificates all into health insurance - including Hodgkin's lymphoma (3 line), liver cell carcinoma (2 line), non-squamous non-small cell lung cancer (line 1 joint), esophageal squamous cancer (2 line) 4 adaptation certificate.
According to relevant reports, including charitable gifts, Hengrui's annual treatment costs of Karelli Zhudao from 1188 million to about 50,000 yuan (before medical insurance reimbursement), that is, according to the 70% reimbursement ratio, the patient actually paid the annual treatment costs fell to about 15,000 yuan, lower than Xinda Biosindili single anti-health insurance reimbursement after 29,000 yuan.
analysis pointed out that from the first four rounds of negotiations, the number of varieties involved in the negotiations showed a continuous upward trend, the average decline in health care negotiations are more than 50%, the fifth round of negotiations is expected to decline significantly.
news of the health care negotiations is circulating in the industry at the same time, there are pharmaceutical companies or personnel adjustments, the relevant medical representatives ready to carry out new career planning discussions are heating up.
2, a group of pharmaceutical representatives or affected related products can enter health insurance, how the decline, what adaptive disorders, with adaptive diseases whether there are other products in the medical insurance catalog, into the medical insurance catalog after the hospital access, pharmaceutical companies in the product into health insurance, will not carry out relevant indicators adjustment or even team restructuring, are important factors that may affect the daily work of pharmaceutical representatives.
first of all, some products with strong clinical needs into health insurance, the high probability is to get an increase in volume.
For example, data show that Thaksin's D-1, the first PD-1 to enter health insurance last year, has grown at a significant rate since it entered health insurance, with first-half 2020 results showing that Dabshu's sales in just six months reached 920.9 million yuan, up 177.7 percent year-on-year.
addition, the two products, QutoZhu Monoanti and Oghithini, both achieved rapid release after being negotiated for inclusion in health insurance.
Recently, the National Health Insurance Administration also stressed in a reply letter to ensure that the negotiation of drug health insurance landing related measures - "not to the total cost control, total cost control of health care, "drug proportion" and other reasons to affect the negotiation of drug supply security."
in order to facilitate the negotiation of drug landing, the Health Insurance Bureau has established a monitoring mechanism for the landing of negotiated medicines, according to the results of the monitoring, the actual reimbursement rate of negotiated drugs is more than 60%."
But there is also a view that access to health insurance does not mean to enter the hospital, because the proportion of drugs and different hospitals of the new drug admission system is different, some products even after entering the health insurance catalog, in the hospital access link is still facing considerable pressure, or need medical representatives to carry out a lot of related work.
In addition, after entering the health insurance catalog, the indicators of the relevant products will also face adjustment, if after entering health insurance, the indicators do not improve, that is responsible for the product's relevant pharmaceutical representatives, in a period of time next year, the performance of the pressure may be relatively small, or even hope to get a good bonus.
if the indicator doesn't rise with the water, and more segments are added to Medicare, the situation facing medical representatives may not be so optimistic.
addition, the ease with which medical representatives work at a later stage is determined by the fact that the same adaptation, with or without other products, is covered by health insurance.
Of course, the most stressed pharmaceutical representatives may be the same adaptive competition into the health care catalog, but their own products because of the decline is not enough reasons, missed the annual into the health insurance catalog window of the batch.
analysis suggests that this year's highly competitive PD-1-related pharmaceutical representatives may face the above problems, specifically - in addition to Cynda Bio's Xindili mono-resistance this year confirmed not to participate in health-care negotiations, AstraZeneta's Duvalli-Yu mono-resistance, Squipp's Navuli Yudao, Mosadong's Paboli Pearl Single Resistance, Roche's Art Pearl Monomass, and Baiji Shenzhou's Tyreli Pearl Single Resistance, Junshi Bio's Terripley Single Resistance, Hengrui Pharmaceutical's Karelli Pearl Single Resistance are all in the health care negotiations on the field.
If the end result is really only Henri's Karelli Zhu single anti-4 adaptive diseases into health insurance, then Hengrui is expected to further expand its market advantage, or even hope to occupy half of the market share.
So whether it's TheIndili mono-resistance, which is already covered by Medicare but is more expensive, or other products related to the remaining six drug companies that may not be able to get into health insurance, or dozens of mono-resistance products that are still waiting for a follow-up listing at the clinical stage, there may be further market pressure, and of course the final outcome will have to wait for the final announcement from the National Health Care Administration.
is finally worth noting that health care is not once and for all.
increase support for access to innovative drugs as medicare insists on changing birds.
At present, China's medical insurance directory has entered the era of dynamic adjustment, basically once a year, the time limit for new drugs into health insurance is relaxed, the number of new drugs eligible for negotiations has also increased significantly, whether it is new medical insurance enterers, or post-entry, may face continuous adjustment.
and the ability to obtain reimbursement qualifications in the in-policy market, as well as a series of subsequent factors, will affect the relevant varieties of pharmaceutical companies and responsible pharmaceutical representatives.
relevant medical representatives, but also need to follow the form, actively change.
。